Appian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial Operations

Appian and PSI launch a live AI solution, but long-term impact remains unquantified.

What the company is saying

Appian (NASDAQ:APPN) and PSI CRO jointly announce the launch of their first AI-powered process orchestration solution for clinical trial site identification and selection. The announcement frames this as the initial step in a broader strategy to automate and connect the entire clinical trial lifecycle, emphasizing efficiency, transparency, and speed. PSI highlights its reputation for predictable patient enrollment and on-time delivery, with Kirill Soldatov, Head of Process Improvement at PSI, stating that the new solution is key to building a more connected and scalable operational model. Alexander Motie, Regional Vice President DACH & Eastern Europe at Appian, positions the project as evidence of AI's value when embedded in business processes and describes the partnership as a foundation for further automation and innovation. The release underscores Appian's recognition as a Leader in the 2026 Gartner Magic Quadrant for Business Orchestration and Automation Technologies. The messaging is confident and forward-looking, focusing on platform scalability and future expansion rather than immediate financial or commercial outcomes.

What the data suggests

The only quantified operational metric is PSI's on-time delivery of clinical trials, which remained above 90% in 2026. PSI employs over 3,500 people across 58 countries as of September 2026, indicating significant global scale. The new AI-powered solution is already live and integrates with PSI's core systems and Appian's AI capabilities, automating previously manual steps in site selection. No financial figures, contract values, or adoption rates for the new product are disclosed. The announcement does not provide period-over-period comparisons or evidence of direct impact from the solution on PSI's operational metrics. The claims of improved efficiency, predictability, and cost reduction are forward-looking and not supported by specific data. The evidence is limited to operational scale and a realised product launch, with the broader platform benefits remaining aspirational.

Analysis

The announcement is upbeat, highlighting the launch of a joint AI-powered solution that is already live, which is a realised milestone. However, much of the narrative is forward-looking, emphasizing a 'first step' in a broader platform strategy and repeatedly referencing future goals such as improved efficiency, scalability, and further automation across the clinical trial lifecycle. The majority of key claims about impact, platform expansion, and benefits are aspirational, with no disclosed financial, revenue, or profitability metrics to substantiate near-term value creation. Operational data (on-time delivery, workforce size, global reach) pertain to PSI's historical performance, not to the new solution's impact. There is no evidence of a large capital outlay or immediate earnings impact, but the benefits of the broader platform are positioned as long-term and uncertain. The gap between the realised product launch and the ambitious language about future transformation inflates the signal moderately.

Risk flags

• ●The announcement lacks any financial disclosure related to the new solution, such as revenue impact, contract value, or adoption metrics. This limits an investor's ability to assess the commercial significance of the launch.
• ●Most of the stated benefits—such as improved efficiency, predictability, and cost reduction—are forward-looking and unquantified, creating a risk that the realised impact may fall short of the ambitious narrative.
• ●The broader platform strategy is described as a vision with further use cases to be evaluated, rather than a committed, scheduled roadmap. This introduces execution risk, as the pace and scale of future development remain uncertain.

Bottom line

Appian and PSI have delivered a live AI-powered solution for automating clinical trial site selection, marking a tangible operational milestone. PSI's operational scale is substantial, with over 3,500 employees and a presence in 58 countries, and its on-time delivery metric remains above 90% in 2026. Despite these operational strengths, the announcement does not disclose any financial metrics or adoption data tied to the new solution, making it difficult to gauge commercial impact or near-term value creation. The partnership is positioned as the foundation for a larger platform strategy, but the timeline and scope for broader benefits are undefined. The most important takeaway is that while a real product is now live, investors have no visibility into its financial contribution or measurable outcomes. Future updates should provide concrete adoption, revenue, or efficiency data to clarify the solution's value.

Announcement summary

(NASDAQ:APPN) Appian and PSI CRO have launched their first joint AI-powered process orchestration solution for clinical trial site identification and selection. The new solution automates and streamlines the site selection process across therapeutic areas, indications, and geographies, integrating previously manual and decentralized steps into a single digital workflow. The solution is live and marks the first step in a broader platform strategy to connect automation, AI-powered capabilities, and process orchestration across the full clinical trial lifecycle. The platform integrates with PSI's core systems and data warehouse, as well as Appian's AI and process intelligence capabilities, to provide real-time insight into process performance and manage routing and exceptions. PSI is recognized for predictable patient enrollment across multiple therapeutic areas and is known for delivering complex clinical trials on time. The solution aims to create a scalable foundation for more predictable, accurate, and timely site selection worldwide, with the goal of reducing or eliminating non-enrolling sites and patient enrollment delays. Appian was recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT). Kirill Soldatov, Head of Process Improvement at PSI, stated that the solution is an important step in rethinking and connecting operational processes, and that building a more connected operational model through automation and AI creates a scalable foundation for improved site selection. Alexander Motie, Regional Vice President DACH & Eastern Europe at Appian, commented that the project demonstrates the value of embedding AI in business processes and that the partnership aims to create a flexible, long-term foundation for further automation and innovation. PSI and Appian plan to evaluate further use cases to extend AI-powered process orchestration across the clinical trial lifecycle, with the goal of shortening clinical studies, increasing predictability, introducing new products to market, and driving down costs for consumers. PSI's on-time delivery of clinical trials metric remained above 90% in 2026. PSI employs over 3,500 people across 58 countries as of September 2026. PSI celebrated its 30th year of business in 2025 as the only fully independent and privately owned mid-sized CRO. PSI's global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.

Disagree with this article?